These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 12661407)

  • 21. Cell death in polyglutamine diseases.
    Evert BO; Wüllner U; Klockgether T
    Cell Tissue Res; 2000 Jul; 301(1):189-204. PubMed ID: 10928291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanisms of neurodegeneration in polyglutamine diseases].
    Tsuji S
    Rinsho Shinkeigaku; 2003 Nov; 43(11):901-2. PubMed ID: 15152498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
    Wyttenbach A
    J Mol Neurosci; 2004; 23(1-2):69-96. PubMed ID: 15126694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Research progress in roles of microRNA in polyglutamine diseases].
    Shi YT; Jiang H; Tang BS
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):406-9. PubMed ID: 20677146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
    Ross CA
    Neuron; 2002 Aug; 35(5):819-22. PubMed ID: 12372277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential therapeutic targets in polyglutamine-mediated diseases.
    Katsuno M; Watanabe H; Yamamoto M; Sobue G
    Expert Rev Neurother; 2014 Oct; 14(10):1215-28. PubMed ID: 25190502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of chaperones on polyglutamine diseases.
    Kobayashi Y; Sobue G
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):165-8. PubMed ID: 11719246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch.
    Igarashi S; Koide R; Shimohata T; Yamada M; Hayashi Y; Takano H; Date H; Oyake M; Sato T; Sato A; Egawa S; Ikeuchi T; Tanaka H; Nakano R; Tanaka K; Hozumi I; Inuzuka T; Takahashi H; Tsuji S
    Nat Genet; 1998 Feb; 18(2):111-7. PubMed ID: 9462738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of proteolysis in polyglutamine disorders.
    Tarlac V; Storey E
    J Neurosci Res; 2003 Nov; 74(3):406-16. PubMed ID: 14598317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
    Butler R; Bates GP
    Nat Rev Neurosci; 2006 Oct; 7(10):784-96. PubMed ID: 16988654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways.
    Gunawardena S; Goldstein LS
    Arch Neurol; 2005 Jan; 62(1):46-51. PubMed ID: 15642849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic opportunities in polyglutamine disease.
    Hughes RE; Olson JM
    Nat Med; 2001 Apr; 7(4):419-23. PubMed ID: 11283667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease.
    Mackenzie IR; Butland SL; Devon RS; Dwosh E; Feldman H; Lindholm C; Neal SJ; Ouellette BF; Leavitt BR
    BMC Neurol; 2006 Aug; 6():32. PubMed ID: 16945149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteasome degrades soluble expanded polyglutamine completely and efficiently.
    Michalik A; Van Broeckhoven C
    Neurobiol Dis; 2004 Jun; 16(1):202-11. PubMed ID: 15207277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dentatorubral-pallidoluysian atrophy (DRPLA)--discovery of the disease, DRPLA gene and the pathophysiology].
    Tsuji S
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1287-9. PubMed ID: 11464481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects.
    Bonsor M; Ammar O; Schnoegl S; Wanker EE; Silva Ramos E
    Proteomics; 2024 Jun; 24(12-13):e2300114. PubMed ID: 38615323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular pathology of dentatorubral-pallidoluysian atrophy.
    Kanazawa I
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1069-74. PubMed ID: 10434307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased aggregation of polyleucine compared with that of polyglutamine in dentatorubral-pallidoluysian atrophy protein.
    Suzuki Y; Jin C; Yazawa I
    Neurosci Lett; 2013 Sep; 552():156-61. PubMed ID: 23933208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
    Reis SD; Pinho BR; Oliveira JMA
    Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Huntington's disease: trinucleotide disease or polyglutamine disease?].
    Ide K; Nukina N; Kanazawa I
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1540-1. PubMed ID: 8752457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.